Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Boehringer Ingelheim To Develop Cancer Drugs Aimed At Degrading Proteins

XTALKS VITALS NEWS

FDA

“We are very excited to partner with Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies,” said Dr. Alessio Ciulli, Associate Professor of Chemical and Structural Biology at the University of Dundee.

Tweetables from this article:

Tweet: Boehringer Ingelheim will develop a new class of proteolytic #cancer drugs http://ctt.ec/0y_j4+Boehringer Ingelheim will develop a new class of proteolytic cancer drugs.

Tweet: PROTACs have the potential to play a role in the treatment of cancer as well as other diseases http://ctt.ec/l3c84+PROTACs have the potential to play a role in the treatment of cancer as well as other diseases.

Share this!

July 15, 2016 | by Sarah Massey, M.Sc.

In collaboration with the researchers at the University of Dundee in Scotland, pharmaceutical company Boehringer Ingelheim will develop a new class of proteolytic cancer drugs. The drugs – named proteolysis targeting chimeric molecules (PROTACs) – will be designed to use the cell’s own housekeeping system to degrade proteins that could lead to the development of diseases like cancer.

By simultaneously binding to an ubiquitin ligase and a protein, PROTACs can trigger a cellular process capable of breaking-down the target molecule. As researchers have used RNAi screens to identify potential disease-causing proteins – including the bromodomain and extraterminal (BET) domain family – PROTACs have the potential to play a role in the treatment of cancer as well as other diseases.

“We believe our approach has the potential to fundamentally transform how we tackle protein targets to fight disease,” said Dr. Alessio Ciulli, Associate Professor of Chemical and Structural Biology at the University of Dundee. “We are very excited to partner with Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies.”



The University of Dundee is a leader in PROTAC research, and teaming up with Boehringer Ingelheim could push the technology from experimental to practical. Despite the platform’s past issues, the team could make some major headway on PROTAC development.

Research into the protein-degrading molecules began 16 years ago, but many researchers have found it challenging to identify small molecule drug candidates with sufficient binding affinity and specificity for ubiquitin ligases.

According to recent research published by Ciulli’s team, the researchers have identified a drug candidate capable of targeting a protein – named BRD4 – which has been implicated in acute myeloid leukemia, ovarian carcinoma and chronic obstructive pulmonary disease. “This is a prime example of an industry-academia collaboration to establish a disruptive new approach to drug discovery, initially developed in academia, and to enable its translation all the way to benefit patients,” said Ciulli.


Keywords: Cancer, Drug Development, Pharmaceuticals


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.